News for Cellectis S.A. (CLLS)

Cellectis S.A. (NASDAQ:CLLS) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ETCompany ParticipantsArthur Stril - CFO and Chief Business...

Shares of Rubrik, Inc. RBRK rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issu...

â—‹ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease

**media[566162]**

Cellectis S.A announces potential resale of 44M shares by AstraZeneca Holdings B.V.

Cellectis stock plunges to 52-week low at $1.52 amid market challenges

Cellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ETCompany ParticipantsArthur Stril - Interim Chief Financial...

Global Genome Editing Market size was valued at USD 8.99 billion in 2023 to USD 31.15 billion by 2031, growing at a CAGR of 16.80% during the forecast...

Cellectis S.A. offers innovative CAR-T therapies for cancer with promising pipeline candidates like UCART22 for ALL and CLLS52. Learn more on CLLS stock here.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Genetic Engineering...

The high prevalence of infectious diseases and cancer, coupled with rapid advancements in sequencing and genome editing technologies, is driving...

Statuts de médicament orphelin et de médicament pour une maladie pédiatrique rare accordés par la FDA et statut de médicament orphelin accordé par la...

Caribou Biosciences, Inc.'s disappointing results in Phase 1 clinical trial for CB-010, led to a 45% stock price decline. Learn more on CRBU stock here.

The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market Size is Expected to Reach USD 34.75...

Florida-based ShiftPixy, Inc. (PIXY) is up over 30 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

•  Cellectis annonce la réalisation de l’investissement additionnel d’AstraZeneca •  Situation de trésorerie de 143 millions de dollars au 31 mars...

•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 20241; cash...

The Global Gene Therapy Market Size was valued at USD 7.65 Billion in 2022 and the Worldwide Gene Therapy Market Size is expected to reach USD 49.21...

Cellectis S.A. (CLLS) is up over 168% in Wednesday's pre-market trading. Here is the list of the other major pre-market movers..